# Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer

> **NCT01992952** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Velindre NHS Trust** · enrollment: 149 (actual)

## Conditions studied

- Estrogen Receptor Positive Breast Cancer

## Interventions

- **DRUG:** AZD5363
- **DRUG:** Placebo
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT01992952
- **Lead sponsor:** Velindre NHS Trust
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-05-07
- **Primary completion:** 2019-03
- **Final completion:** 2025-12-31
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2025-11-26

## Collaborators

- AstraZeneca
- Cenduit LLC
- Covance
- Cardiff and Vale University Health Board

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01992952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01992952, "Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01992952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*